Mechanisms of Intestinal Barrier Disruption Mediated by Gut-Platelet 5-Hydroxytryptamine Signaling in Kawasaki Disease Systemic Vasculitis

Status

Recruiting

Phases

Early Phase 1

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR2400080034

Enrollment

Unknown

Registered

2024-01-18

Start date

2024-01-31

Completion date

Unknown

Last updated

2024-01-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Kawasaki disease

Interventions

IVIG sensitive group/ IVIG unresponsive group/ CAL group:nothing

Eligibility

Sex/Gender

All

Age

No minimum to 14 Years

Inclusion criteria

Inclusion criteria: ?Meet the relevant diagnostic criteria in the 2020 JPS guideline "Diagnosis of Kawasaki Disease (6th Revision)," and meet the 2020 JCS / JSCS guideline: Diagnosis and management of cardiovascular sequelae of Kawasaki Disease; ?In the acute phase: typical or incomplete Kawasaki disease diagnostic criteria, clinical manifestations include fever, bulbar conjunctiva congestion, mouth mucosa congestion chapped, rash, hand and foot scleroma or palmoplantar erythema, neck lymph node tumefaction, etc. ?Age < 14 years ; ?Complete medical records; ?Perfect heart color ultrasound examiners; ?Child Guardian Informed Consent Study.

Exclusion criteria

Exclusion criteria: ?Congenital cardiomyopathy, heart disease ; ?Children with tumor ; ?Combined chronic infection ; ?People who are allergic to the drugs used .

Design outcomes

Primary

Measure	Time frame
Record the duration of fever after initial IVIG treatment ;Coronary lesions: echocardiographic measurement of coronary artery diameter ;Intestinal permeability ;Determination of 5-HT concentration ;	—

Countries

China

Contacts

Public ContactDandan Lang

Zhuhai Municipal People's Hospital

56414550@qq.com+86 133 6060 8616

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026